- Barclays analyst Warren Ackerman issued a note on Haleon.
- Ackerman says transformation is too slow.
Barclays analyst Warren Ackerman says Haleon's transformation is too slow, with insufficient portfolio resilience and disappointing execution despite strong brands like Advil and Panadol.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.